STOCK TITAN
  1. Home
  2. Sec-filings
  3. RIGL
  4. [8-K] RIGEL PHARMACEUTICALS INC Reports Material Event

Rigel (RIGL) secures global VEPPANU license with $70M upfront and milestones

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Rigel Pharmaceuticals has entered into an exclusive, royalty-bearing worldwide license agreement with Arvinas entities and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant) and related products. VEPPANU is approved in the United States for certain ER+, HER2‑negative, ESR1‑mutated advanced or metastatic breast cancer.

Rigel will pay an upfront $70 million, up to $15 million tied to transition activities, and up to $320 million in potential regulatory and sales milestone payments, plus tiered royalties from the mid‑teens to mid‑twenties on net sales. Rigel will lead global development and commercialization, while reimbursing specified ongoing development costs up to $40 million. The agreement becomes effective after expiration or termination of the applicable Hart‑Scott‑Rodino antitrust waiting period.

Positive

  • None.

Negative

  • None.

Insights

Rigel secures global rights to an approved breast cancer drug with sizable payment and royalty obligations.

Rigel is obtaining an exclusive worldwide license to VEPPANU (vepdegestrant), already approved in the U.S. for a defined ER+, HER2‑negative, ESR1‑mutated metastatic breast cancer population. This shifts Rigel further into commercial-stage oncology, adding an on‑market product rather than an early pipeline asset.

Financially, the structure combines a $70 million upfront payment, up to $15 million for transition, and up to $320 million in milestones, plus tiered royalties from the mid‑teens to mid‑twenties on net sales. Rigel also reimburses up to $40 million of ongoing development costs while assuming primary responsibility for global development and commercialization.

The agreement includes commercially reasonable efforts obligations and can terminate for breach, insolvency, or at Rigel’s convenience. Effectiveness depends on Hart‑Scott‑Rodino waiting‑period expiration, so timing of closing hinges on that regulatory step. Actual value will depend on VEPPANU uptake and achievement of the specified sales and regulatory milestones.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Upfront payment $70 million Paid by Rigel to licensors at signing of license
Transition payment $15 million Payable upon successful completion of specified transition activities
Total potential milestones $320 million Regulatory and sales milestone payments under the agreement
Regulatory milestones $60 million Portion of milestones tied to specified regulatory events
Sales milestones $260 million Portion of milestones based on net sales thresholds
Development cost reimbursement cap $40 million Cap on Rigel reimbursement of certain ongoing development costs
Royalty range Mid-teens to mid-twenties % Tiered royalties on annual net sales of licensed products
Agreement date May 11, 2026 Date Rigel entered into the license agreement
royalty-bearing license financial
"the Licensors granted Rigel an exclusive, royalty-bearing license to develop, manufacture and commercialize"
A royalty-bearing license is a legal agreement that lets one party use another’s intellectual property—such as a patent, trademark, or copyrighted technology—in exchange for ongoing payments tied to sales, production, or a fixed fee per unit. For investors it signals a predictable cost and revenue sharing: licensors gain a steady income stream with lower operating risk, while licensees may face reduced margins but avoid large upfront development costs, like renting a recipe and paying per cake sold.
milestone payments financial
"the Licensors are eligible to receive up to $320 million in regulatory and sales milestone payments"
Milestone payments are predetermined sums a company agrees to pay or receive when specific development, regulatory, or commercial goals are reached in a partnership or license deal. Think of them like progress bonuses: they turn uncertain future outcomes into conditional cash events, so investors track them as potential sources of revenue, value inflection points, and risk—payments only arrive if the agreed milestones are actually achieved.
tiered royalties financial
"Rigel is also obligated to pay tiered royalties on annual net sales of Licensed Products"
Tiered royalties are a payment structure where the percentage of earnings paid as royalties changes based on different levels of sales or production. For example, a company might pay a smaller percentage on initial sales and a higher percentage as sales increase beyond certain points. This system encourages higher sales by adjusting payments, making it important for investors to understand how revenue sharing may vary as a product or project grows.
commercially reasonable efforts financial
"customary diligence obligations for Rigel to use commercially reasonable efforts to develop and commercialize"
Hart-Scott-Rodino Antitrust Improvements Act regulatory
"subject to the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976"
A U.S. law that requires companies planning large mergers or acquisitions to notify federal antitrust authorities and wait for review before completing the deal. Think of it like applying for a building permit: regulators check whether the combined business would unfairly hurt competition and can clear the deal, impose changes, or seek to stop it, so the process affects transaction timing, cost, and whether expected benefits reach investors.
indemnification financial
"The Agreement contains customary provisions relating to, among other things, intellectual property, indemnification, confidentiality"
A contractual promise to cover losses, expenses, or legal claims that arise from specified events, such as breaches of representations or third‑party lawsuits. For investors, indemnification matters because it shifts potential financial risk and future cash outflows from one party to another, similar to a friend agreeing to pay your bill if you’re sued, and can affect deal value, expected returns, and contingent liabilities on the balance sheet.

FAQ

What agreement did Rigel Pharmaceuticals (RIGL) sign with Pfizer and Arvinas?
Rigel signed an exclusive, worldwide, royalty-bearing license for VEPPANU (vepdegestrant) and related products. The deal covers development, manufacturing, and commercialization rights, with Rigel assuming primary responsibility once transition activities are completed and the agreement becomes effective after Hart-Scott-Rodino review.

How much will Rigel Pharmaceuticals (RIGL) pay upfront for the VEPPANU license?
Rigel will pay an upfront $70 million to the licensors for the VEPPANU license. It also agreed to pay up to $15 million tied to successful completion of certain transition activities, plus additional potential regulatory and sales milestone payments over the product’s lifecycle.

What milestone payments are included in Rigel’s VEPPANU license deal?
The licensors may receive up to $320 million in milestone payments. This includes up to $60 million tied to specified regulatory milestones and up to $260 million linked to achieving defined net sales thresholds for VEPPANU and related licensed products worldwide.

What royalties will Rigel Pharmaceuticals (RIGL) owe on VEPPANU sales?
Rigel will pay tiered royalties on annual net sales of VEPPANU and related products. The royalty rates range from the mid-teens to mid-twenties percentages, subject to certain reductions and customary adjustments, and continue country-by-country until the applicable royalty term expires.

Who is responsible for developing and commercializing VEPPANU under the Rigel license?
Rigel will have sole rights and primary responsibility for developing and commercializing VEPPANU worldwide. Pfizer will continue certain ongoing development activities during transition, with Rigel reimbursing specified costs up to $40 million, before Rigel fully leads global development and commercialization efforts.

When does Rigel’s VEPPANU license agreement become effective?
The license agreement becomes effective after expiration or termination of the applicable Hart-Scott-Rodino antitrust waiting period. This U.S. regulatory review is required for certain transactions, so the deal’s effectiveness depends on completion of that process before Rigel fully assumes licensed rights.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001034842false00010348422026-05-112026-05-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 11, 2026
RIGEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
0-2988994-3248524
(Commission File No.)(IRS Employer Identification No.)
611 Gateway Boulevard
Suite 900
South San Francisco, CA
94080
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (650) 624-1100
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class
Trading
Symbol(s)
Name of Each Exchange on Which
Registered
Common Stock, par value $0.001 per shareRIGLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Item 1.01.    Entry into a Material Definitive Agreement.
On May 11, 2026, Rigel Pharmaceuticals, Inc. (“Rigel” or the “Company”) entered into a License Agreement (the “Agreement”) with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. (collectively, the “Licensors”).

Pursuant to the Agreement, the Licensors granted Rigel an exclusive, royalty-bearing license to develop, manufacture and commercialize VEPPANUTM (vepdegestrant) and related products (the “Licensed Products”) worldwide. VEPPANU is approved in the United States for the treatment of adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.

Under the terms of the Agreement, Rigel has agreed to pay the Licensors an upfront payment of $70 million and an additional $15 million upon the successful completion of certain transition activities. In addition, the Licensors are eligible to receive up to $320 million in regulatory and sales milestone payments, including up to $60 million upon the achievement of specified regulatory milestones and up to $260 million based on the achievement of specified net sales thresholds. Rigel is also obligated to pay tiered royalties on annual net sales of Licensed Products ranging from the mid-teens to mid-twenties percentages, subject to certain reductions and customary adjustments, and to share a portion of sublicense revenue with the Licensors at tiered rates that decrease over time. In connection with the transition of the Licensed Products, Pfizer will continue to be responsible for certain ongoing development activities, and Rigel has agreed to reimburse the Licensors for certain development costs and expenses incurred in connection with such activities, up to an aggregate amount of $40 million.

Under the Agreement, Rigel will have the sole rights and will be primarily responsible for the development and commercialization of the Licensed Products worldwide, subject to certain transition activities to be performed by the Licensors. The Agreement includes customary diligence obligations for Rigel to use commercially reasonable efforts to develop and commercialize the Licensed Products, including to seek regulatory approvals in specified major markets. The Agreement will remain in effect on a product-by-product and country-by-country basis until the expiration of the applicable royalty term for each Licensed Product in each country, after which the license becomes fully paid-up and perpetual. The Agreement may be terminated by either party under customary circumstances, including for material breach or certain insolvency events, and by Rigel for convenience upon prior written notice. The Agreement contains customary provisions relating to, among other things, intellectual property, indemnification, confidentiality, and representations and warranties.

The effectiveness of the Agreement is subject to the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which the Company intends to file as an exhibit to its periodic reports, subject to customary redactions.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 12, 2026
RIGEL PHARMACEUTICALS, INC.
By:/s/ Raymond J. Furey
Raymond J. Furey
Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents